All Research Studies
Browse all 55 peer-reviewed studies that have shaped our understanding of peptide mechanisms, dosing protocols, and safety considerations.
Thymosin β4 and its Degradation Products in Ischemia-Reperfusion Injury and Tissue Repair
Goldstein & Kleinman examine thymosin β4's role in ischemia-reperfusion injury and tissue repair mechanisms.
The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity
Sikiric et al. explore BPC-157's pleiotropic beneficial activity and its possible relations with neurotransmitter activity.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Literature and patent review by Józwiak et al. covering BPC-157's multifunctional properties and potential medical applications.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
SELECT trial by Lincoff et al. evaluating semaglutide's cardiovascular outcomes in patients with obesity without diabetes.
Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates BDNF and NGF
Dolotov et al. demonstrate Semax's activation of BDNF and NGF expression as an ACTH(4-10) analogue with nootropic properties.
Mitochondria-Targeted Peptide SS-31 Ameliorates Oxidative Stress
Szeto explores how the mitochondria-targeted peptide SS-31 ameliorates oxidative stress and mitochondrial dysfunction.
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Zolotarev et al. investigate Selank's effects on gene expression in GABAergic neurotransmission pathways.
Bremelanotide for Female Sexual Dysfunctions (RECONNECT Trials)
Kingsberg et al. present RECONNECT trial results for bremelanotide (PT-141) in female sexual dysfunction treatment.
The Melanocortin Receptors: Lessons from Knockout Models
Mountjoy et al. review melanocortin receptor biology and insights from knockout models relevant to Melanotan II activity.
Two Years of Continuous GH-Releasing Hormone(1-44) Administration in Growth Hormone Deficiency
Corpas et al. evaluate two years of continuous GHRH(1-44) administration for growth hormone deficiency treatment.
All studies loaded.